


## Changes in 2009 Sales Based on Health Disorders

Changes in sales in EUR million



<sup>1</sup> and other immune system disorders

<sup>2</sup> drugs affecting the renin-angiotensin system

Disorders of more than +/- EUR 60 million

Source: IGES

Sales increases were recorded mainly for the treatment of serious and chronic diseases, especially mental illness and rheumatic and cardiovascular diseases. Decreasing sales were recorded for categories of diseases for which classes of active ingredients used could be prescribed more cost-effectively due to expired patents or price reductions. To this must be added a normalization in the usage frequency of two vaccines, which underwent increased demand in 2008 due to vaccination recommendations.